modelR03AK12

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:SalmeterolAndBudesonide
ATC code:R03AK12
route:inhalation
compartments:2
dosage:50mg
volume of distribution:160L
clearance:100L/h
other parameters in model implementation

A fixed-dose combination of salmeterol, a long-acting beta-2 adrenergic agonist (LABA), and budesonide, an inhaled corticosteroid (ICS). This combination is used as a maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation and bronchodilation. It is approved and commonly used today for these indications.

Pharmacokinetics

Pharmacokinetic parameters estimated for healthy adult subjects after inhalation based on published data for individual components; no direct published PK model for the fixed-combination inhaler product exists.

References

  1. Latorre, M, et al., & Paggiaro, P (2015). Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulmonary pharmacology & therapeutics 30 44–50. DOI:10.1016/j.pupt.2014.10.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25445928

  2. Kim, D, et al., & Lockey, R (2009). Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma. Expert opinion on drug metabolism & toxicology 5(8) 933–940. DOI:10.1517/17425250903127226 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19619072

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)